Axonics, Inc. (NASDAQ: AXNX) has announced the pricing of its underwritten public offering of 1,750,000 shares of common stock, set to close on August 5, 2022. The underwriter has a 30-day option to purchase an additional 262,500 shares. The net proceeds will be used for working capital and general corporate purposes, which may include a potential $35 million milestone payment related to the acquisition of Contura Limited. BofA Securities is the sole book-running manager for this offering.
Axonics, a medical technology company focused on bladder and bowel dysfunction, has initiated a proposed underwritten public offering of 1,750,000 shares of its common stock, with an option for underwriters to purchase an additional 262,500 shares. The proceeds will support working capital and may include a $35 million milestone payment related to its acquisition of Contura Limited. BofA Securities is the sole book-running manager for the offering, which is subject to market conditions. The shares are offered under a previously filed registration statement with the SEC.
Axonics, Inc. reported record quarterly revenue of $69 million for 2Q22, marking a 50% year-over-year increase. Fiscal year 2022 revenue guidance has been revised upward to $253 million, a 40% increase compared to 2021. Sacral neuromodulation revenue soared by 39%, driven by the broad launch of the Axonics F15™ system. Bulkamid® also achieved record sales, projecting treatment for 50,000 women in 2022. Gross margin improved to 72.8%, though operating expenses rose, leading to a net loss of $21.4 million this quarter.
Axonics, Inc. (NASDAQ: AXNX) will release its second quarter 2022 financial results on August 1, 2022, after market close. A conference call is scheduled for 4:30 p.m. Eastern Time to discuss these results. Registration is required for participation via telephone. Axonics specializes in medical technology for bladder and bowel dysfunction, recently recognized as a top company in the Deloitte Technology Fast 500 and the Financial Times rankings. Their products include sacral neuromodulation systems and Bulkamid® for urinary incontinence.
Axonics, Inc. (NASDAQ: AXNX) has submitted a premarket approval supplement to the FDA for its fourth-generation rechargeable sacral neuromodulation implantable neurostimulator (INS). This new device reduces recharging frequency to once every six months, compared to the monthly requirement of the previous version. Axonics anticipates FDA approval in Q4 2022 and aims for product shipments to begin in Q1 2023. The company recently gained FDA approval for its recharge-free system, enhancing market potential in bladder and bowel dysfunction treatments.
Axonics, Inc. (Nasdaq: AXNX) reported Q1 2022 financial results, showing net revenue of $48.4 million, a 41% increase from Q1 2021. Sacral neuromodulation revenue reached $39.1 million, while Bulkamid revenue was $9.4 million, marking a 72% increase year-over-year. Despite a net loss of $22.7 million, cash reserves stood at $213.2 million. The company updated its fiscal year 2022 revenue guidance to $238 million, up 32% from 2021. The launch of the Axonics F15™ and a new advertising campaign are expected to boost market presence.
Axonics, a medical technology company, will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 12:20 p.m. ET. The presentation will be available via live webcast and on their investor relations website. Based in Irvine, California, Axonics specializes in innovative solutions for bladder and bowel dysfunction, including sacral neuromodulation systems and Bulkamid® for urinary incontinence. The company ranks No. 1 on Deloitte's 2021 Technology Fast 500 and among the top 500 fastest-growing companies by the Financial Times.
Axonics, Inc. has launched the Axonics F15, a recharge-free sacral neuromodulation (SNM) system, across the United States. This device, which received FDA approval in March, boasts a longevity of over 15 years at typical settings and potential for more than 20 years at lower energy. The F15 is 20% smaller than competitors and features constant current stimulation. Physician responses have been positive, indicating strong clinical outcomes. The launch aims to address the needs of millions suffering from bladder and bowel dysfunction, supported by established reimbursement coverage.
Axonics, Inc. (NASDAQ: AXNX) will release its first quarter 2022 financial results on May 5, 2022, after market close. A conference call will follow at 4:30 p.m. ET, accessible via phone or webcast. The company specializes in medical technology for bladder and bowel dysfunction, recently earning recognition on the 2021 Deloitte Technology Fast 500™ and 2022 Financial Times rankings. Axonics offers sacral neuromodulation systems and Bulkamid® for urinary incontinence, addressing conditions affecting millions in the U.S. and Europe.
Axonics, Inc. (NASDAQ: AXNX) has launched a direct-to-consumer television advertising campaign titled Find Real Relief, targeting women with urinary incontinence. The initiative aims to raise awareness of incontinence, reduce the stigma, and promote consulting bladder specialists. Ads are airing in 40 U.S. markets and include a new patient landing page, FindRealRelief.com, which connects patients to healthcare providers. The campaign is expected to drive market expansion for Axonics' sacral neuromodulation therapy.